Detailed Molecular Interactions of Favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza Virus Polymerases In Silico

Detailed Molecular Interactions of Favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza Virus Polymerases In Silico

Favipiravir was initially developed as an antiviral drug against influenza and is currently used in clinical trials against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection (COVID-19). This agent is presumably involved in RNA chain termination during influenza virus replication...

Full description

Bibliographic Details
Main Authors: Mitsuru Sada, Takeshi Saraya, Haruyuki Ishii, Kaori Okayama, Yuriko Hayashi, Takeshi Tsugawa, Atsuyoshi Nishina, Koichi Murakami, Makoto Kuroda, Akihide Ryo, Hirokazu Kimura
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Microorganisms
Subjects:
favipiravir
COVID-19
SARS-CoV-2
influenza
RdRp
in silico
Online Access:https://www.mdpi.com/2076-2607/8/10/1610

Internet

https://www.mdpi.com/2076-2607/8/10/1610

Similar Items